C4 Therapeutics Inc (CCCC)

(90% Positive) C4 Therapeutics Inc (CCCC) Announces Enrollment Update for Initiate Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Nuvalent Inc (NUVL)

(10% Negative) Nuvalent Inc (NUVL) Announces Delay in adult patients Trials for clinically proven kinase targets in cancer Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review